FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977452435> ?p ?o ?g. }

• W2977452435 endingPage "v447" @default.
• W2977452435 startingPage "v447" @default.
• W2977452435 abstract "Abstract Background The B-cell receptor (BCR) signaling pathway plays a central role in the development and survival of several subtypes of non-Hodgkin’s lymphomas (NHL). Despite available agents targeting the BCR pathway, no agents are yet curative, remissions are often short, there continues to be a need for more effective and less toxic therapies in the relapsed/refractory setting HMPL-523 is a selective small molecule inhibitor of the spleen tyrosine kinase (SYK), one of the key kinases of the BCR pathway. There are currently 3 ongoing international clinical studies with HMPL-523, including the present study being conducted in the United States (US), Italy, Poland, and Spain. Preliminary data demonstrate HMPL-523 has promising efficacy in multiple subtypes of lymphoma, with a favorable safety profile. We present here a trial-in-progress description of the ongoing US/EU trial, a phase 1 study that includes a dose-escalation and a dose expansion stage. Trial design Study Population: The target population is adult patients with histologically confirmed relapsed or refractory HL or NHL. To be eligible for enrollment, patients (pts) must have exhausted all approved therapy options available. Objectives: The primary objective is to assess the safety and tolerability of HMPL-523 in pts with relapsed or refractory lymphoma and to determine the maximum-tolerated dose (MTD)/ recommended phase 2 dose (RP2D). Preliminary efficacy in pts with relapsed or refractory lymphoma will be evaluated as a secondary objective in the dose expansion stage. Study Design: Dose-escalation will follow a 3 + 3 design and enroll 6 to 30 pts until the MTD/RP2D is reached. The proposed doses are 100 (1 pt only), 200, 400, 600, and 800 mg, daily in 28-day cycles, administered until disease progression, intolerable toxicity, no further benefit from study treatment, withdrawal, end of study, or death. Expansion stage will further evaluate the MTD/RP2D in ∼50 pts, with ∼10 pts in each cohort of: - Chronic lymphocytic leukemia/small lymphocytic lymphoma, Mantle cell lymphoma, Follicular lymphoma, Marginal zone lymphoma, and Waldenstrom’s macroglobulinemia/ lymphoplasmacytic lymphoma Clinical trial identification NCT03779113. Editorial acknowledgement Hoang-Lan Nguyen, Hutchison MediPharma (US), Inc. Legal entity responsible for the study Hutchison MediPharma, Limited. Funding Hutchison MediPharma, Limited. Disclosure N. Fowler: Honoraria (self), Research grant / Funding (self): Celgene; Honoraria (self), Research grant / Funding (self): Gilead Sciences; Honoraria (self), Research grant / Funding (self): Pharmacyclics; Honoraria (self), Research grant / Funding (self): Roche Pharma AG. W. Jurczak: Advisory / Consultancy, Research grant / Funding (self): Gilead Sciences; Advisory / Consultancy, Research grant / Funding (self): Janssen; Advisory / Consultancy, Research grant / Funding (self): Roche; Advisory / Consultancy, Research grant / Funding (self): Acerta; Advisory / Consultancy, Research grant / Funding (self): Celgene; Advisory / Consultancy: Celtrion; Advisory / Consultancy, Research grant / Funding (self): Sandoz-Novartis; Research grant / Funding (self): Beigene; Research grant / Funding (self): TG Therapeutics; Research grant / Funding (self): Incyte; Research grant / Funding (self): Bayer; Research grant / Funding (self): MediPharma; Research grant / Funding (self): AbbVie. R. Cordoba Mascunano: Advisory / Consultancy, Travel / Accommodation / Expenses: AbbVie; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony: Gilead; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Takeda; Advisory / Consultancy, Speaker Bureau / Expert testimony: Servier; Speaker Bureau / Expert testimony: Bristol-Myers Squibb. P. Abrisqueta Costa: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy: AbbVie. C. Yang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Hutchison MediPharma Ltd. M. Kania: Shareholder / Stockholder / Stock options, Full / Part-time employment: Hutchison MediPharma Ltd. J. Kauh: Shareholder / Stockholder / Stock options, Full / Part-time employment: Hutchison MediPharma Ltd. A.J.M. Ferreri: Advisory / Consultancy, Speaker Bureau / Expert testimony: Kite Pharma; Advisory / Consultancy, Travel / Accommodation / Expenses: Gilead Sciences; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Celgene; Research grant / Funding (self), Travel / Accommodation / Expenses: Roche Pharma AG. All other authors have declared no conflicts of interest." @default.
• W2977452435 created "2019-10-10" @default.
• W2977452435 creator A5013293066 @default.
• W2977452435 creator A5033624338 @default.
• W2977452435 creator A5038196228 @default.
• W2977452435 creator A5042592629 @default.
• W2977452435 creator A5044284041 @default.
• W2977452435 creator A5048066442 @default.
• W2977452435 creator A5055989413 @default.
• W2977452435 creator A5070675863 @default.
• W2977452435 creator A5085410438 @default.
• W2977452435 date "2019-10-01" @default.
• W2977452435 modified "2023-09-27" @default.
• W2977452435 title "A phase I study of HMPL-523, a selective oral anti-spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma" @default.
• W2977452435 doi "https://doi.org/10.1093/annonc/mdz251.040" @default.
• W2977452435 hasPublicationYear "2019" @default.
• W2977452435 type Work @default.
• W2977452435 sameAs 2977452435 @default.
• W2977452435 citedByCount "0" @default.
• W2977452435 crossrefType "journal-article" @default.
• W2977452435 hasAuthorship W2977452435A5013293066 @default.
• W2977452435 hasAuthorship W2977452435A5033624338 @default.
• W2977452435 hasAuthorship W2977452435A5038196228 @default.
• W2977452435 hasAuthorship W2977452435A5042592629 @default.
• W2977452435 hasAuthorship W2977452435A5044284041 @default.
• W2977452435 hasAuthorship W2977452435A5048066442 @default.
• W2977452435 hasAuthorship W2977452435A5055989413 @default.
• W2977452435 hasAuthorship W2977452435A5070675863 @default.
• W2977452435 hasAuthorship W2977452435A5085410438 @default.
• W2977452435 hasBestOaLocation W29774524351 @default.
• W2977452435 hasConcept C121608353 @default.
• W2977452435 hasConcept C126322002 @default.
• W2977452435 hasConcept C142424586 @default.
• W2977452435 hasConcept C170493617 @default.
• W2977452435 hasConcept C191897082 @default.
• W2977452435 hasConcept C192562407 @default.
• W2977452435 hasConcept C2776694085 @default.
• W2977452435 hasConcept C2778820342 @default.
• W2977452435 hasConcept C2779338263 @default.
• W2977452435 hasConcept C2780931953 @default.
• W2977452435 hasConcept C31760486 @default.
• W2977452435 hasConcept C42362537 @default.
• W2977452435 hasConcept C71924100 @default.
• W2977452435 hasConceptScore W2977452435C121608353 @default.
• W2977452435 hasConceptScore W2977452435C126322002 @default.
• W2977452435 hasConceptScore W2977452435C142424586 @default.
• W2977452435 hasConceptScore W2977452435C170493617 @default.
• W2977452435 hasConceptScore W2977452435C191897082 @default.
• W2977452435 hasConceptScore W2977452435C192562407 @default.
• W2977452435 hasConceptScore W2977452435C2776694085 @default.
• W2977452435 hasConceptScore W2977452435C2778820342 @default.
• W2977452435 hasConceptScore W2977452435C2779338263 @default.
• W2977452435 hasConceptScore W2977452435C2780931953 @default.
• W2977452435 hasConceptScore W2977452435C31760486 @default.
• W2977452435 hasConceptScore W2977452435C42362537 @default.
• W2977452435 hasConceptScore W2977452435C71924100 @default.
• W2977452435 hasLocation W29774524351 @default.
• W2977452435 hasOpenAccess W2977452435 @default.
• W2977452435 hasPrimaryLocation W29774524351 @default.
• W2977452435 hasRelatedWork W2351796763 @default.
• W2977452435 hasRelatedWork W2351985199 @default.
• W2977452435 hasRelatedWork W2403502999 @default.
• W2977452435 hasRelatedWork W2491142896 @default.
• W2977452435 hasRelatedWork W2567738959 @default.
• W2977452435 hasRelatedWork W2892184049 @default.
• W2977452435 hasRelatedWork W2923882796 @default.
• W2977452435 hasRelatedWork W3203070334 @default.
• W2977452435 hasRelatedWork W4297834875 @default.
• W2977452435 hasRelatedWork W4366141624 @default.
• W2977452435 hasVolume "30" @default.
• W2977452435 isParatext "false" @default.
• W2977452435 isRetracted "false" @default.
• W2977452435 magId "2977452435" @default.
• W2977452435 workType "article" @default.